Basilea Pharmaceutica, a commercial-stage biopharmaceutical company, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, an affiliate of Pfizer, to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. In addition, Basilea has acquired the rights to a preclinical antifungal compound. Under the terms of the agreement, the company will make an upfront payment of $37 million and potential commercial milestone payments of up to $110 million based on future product sales.
Lenz & Staehelin is advising Pfizer and Amplyx Pharmaceuticals on this transaction. The team includes Tino Gaberthüel (partner, M&A, pictured left), Vincent Huynh Dac (associate, M&A, pictured right) and Stephan Brander (counsel, tax).